About Myrobalan Therapeutics

Myrobalan Therapeutics is developing oral small molecule therapies targeting neuroinflammation and demyelination in central nervous system disorders such as multiple sclerosis and Alzheimer's disease. By utilizing biomarker-guided precision neurology, the company aims to deliver therapeutically relevant treatments with a favorable safety profile and high brain penetration.

```xml <problem> Central nervous system (CNS) disorders like multiple sclerosis and Alzheimer's disease are driven by demyelination and neuroinflammation. Current treatments often lack sufficient efficacy, have unfavorable safety profiles, and do not effectively penetrate the brain. </problem> <solution> Myrobalan Therapeutics is developing oral small molecule therapies designed to address neuroinflammation and promote remyelination in CNS disorders. The company focuses on creating first-in-class and best-in-class treatments with a wide therapeutic margin and high CNS distribution. By leveraging drug discovery expertise, Myrobalan identifies potent, selective, and brain-penetrant compounds that target therapeutically relevant mechanisms. The company is committed to biomarker-guided precision neurology to deliver innovative therapies to appropriate patient populations. </solution> <features> - Oral small molecule therapeutics for CNS disorders - Focus on addressing demyelination and neuroinflammation - Development of first-in-class and best-in-class therapies - High CNS distribution to ensure efficacy - Biomarker-guided precision neurology approach </features> <target_audience> The primary target audience includes patients suffering from CNS diseases such as multiple sclerosis, Alzheimer's disease, ALS, Parkinson's disease, and various demyelinating and degenerative disorders. </target_audience> ```

What does Myrobalan Therapeutics do?

Where is Myrobalan Therapeutics located?

Myrobalan Therapeutics is based in Arlington, United States.

When was Myrobalan Therapeutics founded?

Myrobalan Therapeutics was founded in 2021.

How much funding has Myrobalan Therapeutics raised?

Myrobalan Therapeutics has raised 43000000.

Location

Arlington, United States

Founded

2021

Funding

43000000

Employees

26 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Myrobalan Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

myrotx.com 3K+

Founded 2021 – Arlington, United States

Funding

Estimated Funding

$20M+

Team (25+)

No team information available.

Company Description

Problem

Central nervous system (CNS) disorders like multiple sclerosis and Alzheimer's disease are driven by demyelination and neuroinflammation. Current treatments often lack sufficient efficacy, have unfavorable safety profiles, and do not effectively penetrate the brain.

Solution

Myrobalan Therapeutics is developing oral small molecule therapies designed to address neuroinflammation and promote remyelination in CNS disorders. The company focuses on creating first-in-class and best-in-class treatments with a wide therapeutic margin and high CNS distribution. By leveraging drug discovery expertise, Myrobalan identifies potent, selective, and brain-penetrant compounds that target therapeutically relevant mechanisms. The company is committed to biomarker-guided precision neurology to deliver innovative therapies to appropriate patient populations.

Features

Oral small molecule therapeutics for CNS disorders

Focus on addressing demyelination and neuroinflammation

Development of first-in-class and best-in-class therapies

High CNS distribution to ensure efficacy

Biomarker-guided precision neurology approach

Target Audience

The primary target audience includes patients suffering from CNS diseases such as multiple sclerosis, Alzheimer's disease, ALS, Parkinson's disease, and various demyelinating and degenerative disorders.